(Q45176571)

10 December 2017

title

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant (English)

1 reference

10 December 2017

1 reference

5

1 reference

10 December 2017

2

Michelle Fanale

1 reference

10 December 2017

1

Sally Arai

1 reference

10 December 2017

Sven DeVos

3

1 reference

10 December 2017

Andreas Engert

4

1 reference

10 December 2017

Peter Borchmann

6

1 reference

10 December 2017

Anas Younes

7

1 reference

10 December 2017

Franck Morschhauser

8

1 reference

10 December 2017

Alex McMillan

9

1 reference

10 December 2017

Sandra J Horning

10

1 reference

10 December 2017

publication date

5 June 2013

1 reference

10 December 2017

1 reference

10 December 2017

volume

54

1 reference

10 December 2017

issue

11

1 reference

10 December 2017

page(s)

2531-2533

1 reference

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.798868

10.3109/10428194.2013.798868

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference